5-Iodo-BIIB021 is a HSP90 ligand. 5-Iodo-BIIB021 serves as a Ligand for Target Protein for PROTAC for the synthesis of PROTAC HSP90 degraders, such as PROTAC HSP90 degrader BP3. 5-Iodo-BIIB021 is applicable to breast cancer research [1].
In Vivo, BIIB021 (60 mg/kg; i.p.; daily; 12 days) achieves a 31.82% tumor inhibition rate in a BALB/c mouse 4T1 breast cancer model[1].
References:
[1]. Liu Q, et al. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. European journal of medicinal chemistry. 2022 Jan 15;228:114013.
In Vivo, BIIB021 (60 mg/kg; i.p.; daily; 12 days) achieves a 31.82% tumor inhibition rate in a BALB/c mouse 4T1 breast cancer model[1].
References:
[1]. Liu Q, et al. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. European journal of medicinal chemistry. 2022 Jan 15;228:114013.